Background Here, we report the results of the Japanese subgroup of the phase 3 KEYNOTE-
048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Abstract Background KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3
trial of pembrolizumab (pembro) or pembro+ chemotherapy (chemo) vs EXTREME (E) as …

Background/Aim: This Japanese single-center retrospective cohort study aimed to evaluate
the real-world therapeutic outcomes of pembrolizumab or pembrolizumab plus …

Background/Aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or
platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and …

Background The KEYNOTE-048 and KEYNOTE-040 study have demonstrated the efficacy
of pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck …

Background: KEYNOTE-048 was an open-label, randomized phase 3 study of P or P+
chemotherapy (C) vs EXTREME (E) as first-line systemic therapy for R/M HNSCC …

Background Pembrolizumab plus platinum and fluorouracil is the standard first-line
treatment in patients with recurrent/metastatic head and neck squamous-cell carcinoma …

Background: Cetuximab plus platinum and 5-fluorouracil (5-FU) is the only category 1
evidence-supported combination regimen recommended by current guidelines as first-line …

6000 Background: KEYNOTE-048 is a phase 3 study of P or P+ chemo (C) vs EXTREME (E)
as 1L therapy for R/M HNSCC (NCT02358031). At the second interim analysis (IA2), P …